(NASDAQ: ALT) Altimmune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.
Altimmune's earnings in 2025 is -$83,915,000.On average, 10 Wall Street analysts forecast ALT's earnings for 2025 to be -$103,795,455, with the lowest ALT earnings forecast at -$106,255,853, and the highest ALT earnings forecast at -$106,182,875. On average, 10 Wall Street analysts forecast ALT's earnings for 2026 to be -$128,493,268, with the lowest ALT earnings forecast at -$169,600,689, and the highest ALT earnings forecast at -$112,750,888.
In 2027, ALT is forecast to generate -$109,331,351 in earnings, with the lowest earnings forecast at -$200,251,415 and the highest earnings forecast at -$20,798,708.